- First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
- Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
- Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Reports First Quarter 2024 Financial Results
- Esperion to Participate in Upcoming May Investor Conferences
- Esperion to Report First Quarter 2024 Financial Results on May 7
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
- Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
- Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
More ▼
Key statistics
As of last trade Esperion Therapeutics Inc (0ET:FRA) traded at 2.05, -31.29% below its 52-week high of 2.99, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.05 |
---|---|
High | 2.05 |
Low | 2.05 |
Bid | 2.12 |
Offer | 2.28 |
Previous close | 1.94 |
Average volume | 16.34k |
---|---|
Shares outstanding | 189.46m |
Free float | 188.61m |
P/E (TTM) | -- |
Market cap | 450.92m USD |
EPS (TTM) | -1.00 USD |
Data delayed at least 15 minutes, as of May 23 2024 07:23 BST.
More ▼